Latest Information Update: 27 Sep 2006
At a glance
- Originator Sindan
- Mechanism of Action Estrogen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 27 Sep 2006 Discontinued - Preclinical for Breast cancer in Romania (unspecified route)
- 04 Dec 2000 Preclinical development for Breast cancer in Romania (Unknown route)